{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:11Z","timestamp":1793214611551,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40123-021-00393-8","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:59:41Z","timestamp":1630688381000},"page":"777-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review"],"prefix":"10.1007","volume":"10","author":[{"given":"Jurgen","family":"Sota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo-Maria","family":"Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"393_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2013.02.004","volume":"35","author":"D Wakefield","year":"2013","unstructured":"Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P. Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res. 2013;35:44\u201362. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.02.004.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"393_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1517\/14656566.2013.772982","volume":"14","author":"RM Beardsley","year":"2013","unstructured":"Beardsley RM, Suhler EB, Rosenbaum JT, Lin P. Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother. 2013;14(4):411\u201324. https:\/\/doi.org\/10.1517\/14656566.2013.772982.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"393_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11926-020-0885-y","volume":"22","author":"A Nevares","year":"2020","unstructured":"Nevares A, Raut R, Libman B, Hajj-Ali R. Noninfectious autoimmune scleritis: recognition, systemic associations, and therapy. Curr Rheumatol Rep. 2020;22(4):11. https:\/\/doi.org\/10.1007\/s11926-020-0885-y.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"393_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/bjo.2009.164962","volume":"94","author":"A Roufas","year":"2010","unstructured":"Roufas A, Jalaludin B, Gaskin C, McCluskey P. Subconjunctival triamcinolone treatment for non-necrotising anterior scleritis. Br J Ophthalmol. 2010;94(6):743\u20137. https:\/\/doi.org\/10.1136\/bjo.2009.164962.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"393_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/bjo.2008.150961","volume":"94","author":"P Doctor","year":"2010","unstructured":"Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94(5):579\u201383. https:\/\/doi.org\/10.1136\/bjo.2008.150961.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"393_CR6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","volume":"121","author":"EB Suhler","year":"2014","unstructured":"Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.044.","journal-title":"Ophthalmology"},{"issue":"6","key":"393_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3109\/09273948.2013.863944","volume":"22","author":"A Ragam","year":"2014","unstructured":"Ragam A, Kolomeyer AM, Fang C, Xu Y, Chu DS. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. Ocul Immunol Inflamm. 2014;22(6):469\u201377. https:\/\/doi.org\/10.3109\/09273948.2013.863944.","journal-title":"Ocul Immunol Inflamm"},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajo.2015.12.032","volume":"164","author":"JH Cao","year":"2016","unstructured":"Cao JH, Oray M, Cocho L, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol. 2016;164:22\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2015.12.032.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"393_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/09273948.2017.1299869","volume":"26","author":"C Bottin","year":"2018","unstructured":"Bottin C, Fel A, Butel N, et al. Anakinra in the treatment of patients with refractory scleritis: a pilot study. Ocul Immunol Inflamm. 2018;26(6):915\u201320.","journal-title":"Ocul Immunol Inflamm"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ajo.2016.09.017","volume":"172","author":"JE Knickelbein","year":"2016","unstructured":"Knickelbein JE, Tucker WR, Bhatt N, et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I\/II clinical trial. Am J Ophthalmol. 2016;172:104\u201310. https:\/\/doi.org\/10.1016\/j.ajo.2016.09.017.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"393_CR11","first-page":"1138","volume":"38","author":"C Fabiani","year":"2020","unstructured":"Fabiani C, Sota J, Sainz-de-la-Maza M, et al. Effectiveness of TNF-\u03b1 blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clin Exp Rheumatol. 2020;38(6):1138\u201344.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"393_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/09273940802023786","volume":"16","author":"N Huynh","year":"2008","unstructured":"Huynh N, Cervantes-Castaneda RA, Bhat P, Gallagher MJ, Foster CS. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008;16(3):89\u201393. https:\/\/doi.org\/10.1080\/09273940802023786.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"393_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10067-009-1368-8","volume":"29","author":"JP Restrepo","year":"2010","unstructured":"Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29(5):559\u201361. https:\/\/doi.org\/10.1007\/s10067-009-1368-8.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"393_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/0974-620X.91271","volume":"4","author":"AM Bawazeer","year":"2011","unstructured":"Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol. 2011;4(3):139\u201341. https:\/\/doi.org\/10.4103\/0974-620X.91271.","journal-title":"Oman J Ophthalmol"},{"issue":"12","key":"393_CR15","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/rheumatology\/kev324","volume":"54","author":"S Akhtar","year":"2015","unstructured":"Akhtar S, Babar S, Lightman S, Mason JC. Adalimumab-induced remission of anterior scleritis: a very rare late manifestation of Takayasu arteritis. Rheumatol (Oxford). 2015;54(12):2288\u201390. https:\/\/doi.org\/10.1093\/rheumatology\/kev324.","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"393_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12348-016-0107-y","volume":"6","author":"LE Lawuyi","year":"2016","unstructured":"Lawuyi LE, Gurbaxani A. Refractory necrotizing scleritis successfully treated with adalimumab. J Ophthalmic Inflamm Infect. 2016;6(1):37. https:\/\/doi.org\/10.1186\/s12348-016-0107-y.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"3","key":"393_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","volume":"25","author":"K Durrani","year":"2017","unstructured":"Durrani K, Kempen JH, Ying GS, et al. Systemic immunosuppressive therapy for eye diseases site research group. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2017;25(3):405\u201312. https:\/\/doi.org\/10.3109\/09273948.2015.1134581.","journal-title":"Ocul Immunol Inflamm"},{"key":"393_CR18","doi-asserted-by":"publisher","first-page":"312767","DOI":"10.1136\/bjophthalmol-2018-312767","volume":"2019","author":"SM Sharma","year":"2019","unstructured":"Sharma SM, Damato E, Hinchcliffe AE, et al. Long-term efficacy and tolerability of TNF\u03b1 inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2019;2019:312767. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312767.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"393_CR19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.4103\/ijo.IJO_966_20","volume":"68","author":"S Sadhu","year":"2020","unstructured":"Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India. Indian J Ophthalmol. 2020;68(9):1929\u201333. https:\/\/doi.org\/10.4103\/ijo.IJO_966_20.","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"393_CR20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/bjophthalmol-2015-306902","volume":"100","author":"M Sainz-de-la-Maza","year":"2016","unstructured":"Sainz-de-la-Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Scleritis associated with relapsing polychondritis. Br J Ophthalmol. 2016;100(9):1290\u20134. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306902.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"393_CR21","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.3129\/i09-061","volume":"44","author":"HN Sen","year":"2009","unstructured":"Sen HN, Sangave A, Hammel K, Levy-Clarke G, Nussenblatt RB. Infliximab for the treatment of active scleritis. Can J Ophthalmol. 2009;44(3):e9\u201312. https:\/\/doi.org\/10.3129\/i09-061.","journal-title":"Can J Ophthalmol"},{"issue":"7","key":"393_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archopht.125.7.895","volume":"125","author":"L Sobrin","year":"2007","unstructured":"Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125(7):895\u2013900. https:\/\/doi.org\/10.1001\/archopht.125.7.895.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"393_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/rheumatology\/keh635","volume":"44","author":"D Ashok","year":"2005","unstructured":"Ashok D, Ayliffe WH, Kiely PD. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatol (Oxford). 2005;44(7):950\u20131. https:\/\/doi.org\/10.1093\/rheumatology\/keh635.","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"393_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2018-000250","volume":"4","author":"C Iwahashi","year":"2019","unstructured":"Iwahashi C, Ono H, Haruta M, et al. New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophthalmol. 2019;4(1): e000250. https:\/\/doi.org\/10.1136\/bmjophth-2018-000250.","journal-title":"BMJ Open Ophthalmol"},{"issue":"2","key":"393_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","volume":"111","author":"CC Murphy","year":"2004","unstructured":"Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111(2):352\u20136. https:\/\/doi.org\/10.1016\/S0161-6420(03)00721-8.","journal-title":"Ophthalmology"},{"issue":"3","key":"393_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s10384-008-0652-5","volume":"53","author":"SJ Ahn","year":"2009","unstructured":"Ahn SJ, Oh JY, Kim MK, Wee WR. Treating refractory scleritis with infliximab. Jpn J Ophthalmol. 2009;53(3):286\u20137. https:\/\/doi.org\/10.1007\/s10384-008-0652-5.","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"393_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4321\/s0365-66912004000800010","volume":"79","author":"D D\u00edaz-Valle","year":"2004","unstructured":"D\u00edaz-Valle D, Migu\u00e9lez S\u00e1nchez R, Fern\u00e1ndez Espartero MC, Pascual AD. Tratamiento de la escleritis anterior difusa refractaria con infliximab [Treatment of refractory anterior diffuse scleritis with infliximab]. Arch Soc Esp Oftalmol. 2004;79(8):405\u20138. https:\/\/doi.org\/10.4321\/s0365-66912004000800010.","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"2","key":"393_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/sj.eye.6701457","volume":"19","author":"S Cazabon","year":"2005","unstructured":"Cazabon S, Over K, Butcher J. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye (Lond). 2005;19(2):222\u20134. https:\/\/doi.org\/10.1038\/sj.eye.6701457.","journal-title":"Eye (Lond)"},{"issue":"9","key":"393_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/sj.eye.6701712","volume":"19","author":"Y El-Shabrawi","year":"2005","unstructured":"El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener\u2019s granulomatosis. Eye (Lond). 2005;19(9):1017\u20138. https:\/\/doi.org\/10.1038\/sj.eye.6701712.","journal-title":"Eye (Lond)"},{"issue":"6","key":"393_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.rhu.0000249766.24780.95","volume":"12","author":"II Atchia","year":"2006","unstructured":"Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006;12(6):291\u20133. https:\/\/doi.org\/10.1097\/01.rhu.0000249766.24780.95.","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"393_CR31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00417-007-0634-1","volume":"245","author":"K Weiss","year":"2007","unstructured":"Weiss K, Rieger R, Keitzer R, Pleyer U. Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive therapy. Graefes Arch Clin Exp Ophthalmol. 2007;245(11):1735\u20137. https:\/\/doi.org\/10.1007\/s00417-007-0634-1.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"393_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.eye.6702708","volume":"22","author":"AM Morley","year":"2008","unstructured":"Morley AM, Pavesio C. Surgically induced necrotising scleritis following three-port pars plana vitrectomy without scleral buckling: a series of three cases. Eye (Lond). 2008;22(1):162\u20134. https:\/\/doi.org\/10.1038\/sj.eye.6702708.","journal-title":"Eye (Lond)"},{"issue":"4","key":"393_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.crohns.2008.06.002","volume":"2","author":"EL Culver","year":"2008","unstructured":"Culver EL, Salmon JF, Frith P, Travis SP. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn\u2019s disease: case report and systematic literature review. J Crohns Colitis. 2008;2(4):337\u201342. https:\/\/doi.org\/10.1016\/j.crohns.2008.06.002.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"393_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/03009740802366076","volume":"38","author":"R Lopez-Gonzalez","year":"2009","unstructured":"Lopez-Gonzalez R, Loza E, Jover JA, Benitez Del Castillo JM, Mendez R, Hernandez-Garcia C, Pato E. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol. 2009;38(1):58\u201362. https:\/\/doi.org\/10.1080\/03009740802366076.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"393_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4081\/reumatismo.2009.212","volume":"61","author":"R Herrera-Esparza","year":"2009","unstructured":"Herrera-Esparza R, Avalos-D\u00edaz E. Infliximab treatment in a case of rheumatoid scleromalacia perforans. Reumatismo. 2009;61(3):212\u20135. https:\/\/doi.org\/10.4081\/reumatismo.2009.212.","journal-title":"Reumatismo"},{"issue":"5","key":"393_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.medcli.2009.02.009","volume":"134","author":"GM Abalos-Medina","year":"2010","unstructured":"Abalos-Medina GM, G\u00f3nzalez-Dom\u00ednguez J, Ruiz-Villaverde G, Raya-Alvarez E. Infliximab para el tratamiento de la escleritis anterior necrosante asociada a artritis reumatoide seropositiva [Infliximab in the treatment of necrotizing scleritis associated to seropositive rheumatoid arthritis]. Med Clin (Barc). 2010;134(5):235\u20136. https:\/\/doi.org\/10.1016\/j.medcli.2009.02.009.","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"393_CR37","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1111\/j.1755-3768.2009.01546.x","volume":"88","author":"M Kontkanen","year":"2010","unstructured":"Kontkanen M, Paimela L, Kaarniranta K. Regression of necrotizing scleritis in Wegener\u2019s granulomatosis after infliximab treatment. Acta Ophthalmol. 2010;88(3):e96\u20137. https:\/\/doi.org\/10.1111\/j.1755-3768.2009.01546.x.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"393_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/09273941003624914","volume":"18","author":"M Jabbarvand","year":"2010","unstructured":"Jabbarvand M, Fard MA. Infliximab in a patient with refractory necrotizing scleritis associated with relapsing polychondritis. Ocul Immunol Inflamm. 2010;18(3):216\u20137. https:\/\/doi.org\/10.3109\/09273941003624914.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"393_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10384-010-0889-7","volume":"55","author":"JY Oh","year":"2011","unstructured":"Oh JY, Kim MK, Wee WR. Infliximab for progressive peripheral ulcerative keratitis in a patient with juvenile rheumatoid arthritis. Jpn J Ophthalmol. 2011;55(1):70\u20131. https:\/\/doi.org\/10.1007\/s10384-010-0889-7.","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"393_CR40","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1097\/ICO.0b013e31826218c7","volume":"31","author":"M Hata","year":"2012","unstructured":"Hata M, Nakamura T, Sotozono C, Kumagai K, Kinoshita S, Kurimoto Y. Atypical continuous keratitis in a case of rheumatoid arthritis accompanying severe scleritis. Cornea. 2012;31(12):1493\u20136. https:\/\/doi.org\/10.1097\/ICO.0b013e31826218c7.","journal-title":"Cornea"},{"issue":"20","key":"393_CR41","doi-asserted-by":"publisher","first-page":"30835","DOI":"10.1016\/j.jcjo.2020.11.013","volume":"S0008\u20134182","author":"S Khalili","year":"2020","unstructured":"Khalili S, Mireskandari K. Infliximab for management of severe refractory posterior scleritis in a 9-year-old boy. Can J Ophthalmol. 2020;S0008\u20134182(20):30835\u20138. https:\/\/doi.org\/10.1016\/j.jcjo.2020.11.013.","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"393_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.ICL.0000092064.05514.04","volume":"30","author":"M Hernandez-Illas","year":"2004","unstructured":"Hernandez-Illas M, Tozman E, Fulcher SF, Jundt JW, Davis J, Pflugfelder SC. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;30(1):2\u20135. https:\/\/doi.org\/10.1097\/01.ICL.0000092064.05514.04.","journal-title":"Eye Contact Lens"},{"issue":"3","key":"393_CR43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","volume":"45","author":"JR Smith","year":"2001","unstructured":"Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252\u20137. https:\/\/doi.org\/10.1002\/1529-0131(200106)45:3%3c252::AID-ART257%3e3.0.CO;2-5.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"393_CR44","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","volume":"113","author":"A Galor","year":"2006","unstructured":"Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2006.04.038.","journal-title":"Ophthalmology"},{"issue":"12","key":"393_CR45","first-page":"2727","volume":"30","author":"AN Tiliakos","year":"2003","unstructured":"Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? J Rheumatol. 2003;30(12):2727.","journal-title":"J Rheumatol"},{"issue":"7","key":"393_CR46","doi-asserted-by":"publisher","first-page":"511.e1-6","DOI":"10.1016\/j.jfo.2009.04.029","volume":"32","author":"J Le-Garrec","year":"2009","unstructured":"Le-Garrec J, Marcelli C, Mouriaux F. Les anti-Tnf peuvent-ils induire des scl\u00e9ro-uv\u00e9ites? [Can tumor necrosis factor inhibitors induce sclero-uveitis?]. J Fr Ophtalmol. 2009;32(7):511.e1-6. https:\/\/doi.org\/10.1016\/j.jfo.2009.04.029.","journal-title":"J Fr Ophtalmol"},{"issue":"2","key":"393_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3899\/jrheum.110865","volume":"39","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233\u20139. https:\/\/doi.org\/10.3899\/jrheum.110865.","journal-title":"J Rheumatol"},{"issue":"2","key":"393_CR48","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1111\/j.1755-3768.2010.02090.x","volume":"90","author":"Y Sassa","year":"2012","unstructured":"Sassa Y, Kawano Y, Yamana T, Mashima T, Ishibashi T. A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis. Acta Ophthalmol. 2012;90(2):e161\u20132. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.02090.x.","journal-title":"Acta Ophthalmol"},{"key":"393_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000099265","volume":"92","author":"TA Ferguson","year":"2007","unstructured":"Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy. 2007;92:140\u201354. https:\/\/doi.org\/10.1159\/000099265.","journal-title":"Chem Immunol Allergy"},{"issue":"3","key":"393_CR50","doi-asserted-by":"publisher","first-page":"NP7","DOI":"10.1177\/1120672118823121","volume":"30","author":"R Amer","year":"2020","unstructured":"Amer R, Levinger N. Psoriasis-associated progressive necrotizing posterior scleritis: a 6-year follow-up. Eur J Ophthalmol. 2020;30(3):NP7\u201310. https:\/\/doi.org\/10.1177\/1120672118823121.","journal-title":"Eur J Ophthalmol"},{"key":"393_CR51","doi-asserted-by":"publisher","unstructured":"Dutta-Majumder P, Jayshree G, David RL, Kaushik V. A case of idiopathic necrotizing scleritis with secondary glaucoma treated successfully with golimumab and Ahmed valve implantation. Indian J Ophthalmol. 2019;67(8):1360\u20131362. https:\/\/doi.org\/10.4103\/ijo.IJO_2081_18.","DOI":"10.4103\/ijo.IJO_2081_18"},{"issue":"1","key":"393_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/ICO.0b013e318211400a","volume":"31","author":"PS Tlucek","year":"2012","unstructured":"Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2012;31(1):90\u20131. https:\/\/doi.org\/10.1097\/ICO.0b013e318211400a.","journal-title":"Cornea"},{"issue":"11","key":"393_CR53","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","volume":"89","author":"CM Cheung","year":"2005","unstructured":"Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener\u2019s granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89(11):1542. https:\/\/doi.org\/10.1136\/bjo.2005.075689.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"393_CR54","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/ard.2004.027128","volume":"64","author":"K Ahmadi-Simab","year":"2005","unstructured":"Ahmadi-Simab K, Lamprecht P, N\u00f6lle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren\u2019s syndrome with rituximab. Ann Rheum Dis. 2005;64(7):1087\u20138. https:\/\/doi.org\/10.1136\/ard.2004.027128.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"393_CR55","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","volume":"122","author":"L Joshi","year":"2015","unstructured":"Joshi L, Tanna A, McAdoo SP, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and nonlocalized disease. Ophthalmology. 2015;122(6):1262\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.016.","journal-title":"Ophthalmology"},{"issue":"1","key":"393_CR56","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000486791","volume":"61","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61(1):44\u201350. https:\/\/doi.org\/10.1159\/000486791.","journal-title":"Ophthalmic Res"},{"issue":"12","key":"393_CR57","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00417-015-3198-5","volume":"253","author":"C Recillas-Gispert","year":"2015","unstructured":"Recillas-Gispert C, Serna-Ojeda JC, Flores-Su\u00e1rez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener\u2019s). Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2279\u201384. https:\/\/doi.org\/10.1007\/s00417-015-3198-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"393_CR58","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1080\/09273948.2017.1327602","volume":"26","author":"C You","year":"2018","unstructured":"You C, Ma L, Lasave AF, Foster CS. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener\u2019s). Ocul Immunol Inflamm. 2018;26(8):1166\u201373. https:\/\/doi.org\/10.1080\/09273948.2017.1327602.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"393_CR59","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000342842","volume":"3","author":"J Morarji","year":"2012","unstructured":"Morarji J, Joshi L, Tomkins-Netzer O, Lightman S, Taylor SR. Combined infliximab and rituximab in necrotising scleritis. Case Rep Ophthalmol. 2012;3(3):286\u201390. https:\/\/doi.org\/10.1159\/000342842.","journal-title":"Case Rep Ophthalmol"},{"issue":"2","key":"393_CR60","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/j.1755-3768.2011.02127.x","volume":"90","author":"MK Stilling-Vinther","year":"2012","unstructured":"Stilling-Vinther MK, Pedersen BS. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol. 2012;90(2):e154\u20135. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02127.x.","journal-title":"Acta Ophthalmol"},{"issue":"1 Suppl 57","key":"393_CR61","first-page":"90","volume":"28","author":"G Bussone","year":"2010","unstructured":"Bussone G, Kaswin G, de Menthon M, Delair E, Br\u00e9zin AP, Guillevin L. Macular oedema following rituximab infusion in two patients with Wegener\u2019s granulomatosis. Clin Exp Rheumatol. 2010;28(1 Suppl 57):90\u20132.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"393_CR62","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/bjo.2008.147157","volume":"93","author":"S Chauhan","year":"2009","unstructured":"Chauhan S, Kamal A, Thompson RN, Estrach C, Moots RJ. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol. 2009;93(7):984\u20135. https:\/\/doi.org\/10.1136\/bjo.2008.147157.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"393_CR63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/09273940802331643","volume":"16","author":"S Onal","year":"2008","unstructured":"Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener\u2019s granulomatosis. Ocul Immunol Inflamm. 2008;16(5):230\u20132. https:\/\/doi.org\/10.1080\/09273940802331643.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"393_CR64","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/bjo.2007.133173","volume":"93","author":"PA Kurz","year":"2009","unstructured":"Kurz PA, Suhler EB, Choi D, Rosenbaum JT. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol. 2009;93(4):546\u20138. https:\/\/doi.org\/10.1136\/bjo.2007.133173.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"393_CR65","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24454","volume":"60","author":"SR Taylor","year":"2009","unstructured":"Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener\u2019s granulomatosis. Arthritis Rheum. 2009;60(5):1540\u20137. https:\/\/doi.org\/10.1002\/art.24454.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"393_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/09273941003739928","volume":"18","author":"B Iaccheri","year":"2010","unstructured":"Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18(3):223\u20135. https:\/\/doi.org\/10.3109\/09273941003739928.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"393_CR67","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/09273948.2013.788724","volume":"21","author":"K Bogdanic-Werner","year":"2013","unstructured":"Bogdanic-Werner K, Fernandez-Sanz G, Alejandre Alba N, Ferrer Soldevila P, Romero-Bueno FI, Sanchez-Pernaute O. Rituximab therapy for refractory idiopathic scleritis. Ocul Immunol Inflamm. 2013;21(4):329\u201332. https:\/\/doi.org\/10.3109\/09273948.2013.788724.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"393_CR68","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1097\/IOP.0000000000000251","volume":"32","author":"SK Kasi","year":"2016","unstructured":"Kasi SK, Kim HJ, Basham RP, et al. Idiopathic orbital inflammation associated with necrotizing scleritis and temporal bone inflammation. Ophthalmic Plast Reconstr Surg. 2016;32(4):e77\u20139. https:\/\/doi.org\/10.1097\/IOP.0000000000000251.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"393_CR69","doi-asserted-by":"publisher","unstructured":"Hardy S, Hashemi K, Catanese M, et al. Necrotising scleritis and peripheral ulcerative keratitis associated with rheumatoid arthritis treated with rituximab. Klin Monbl Augenheilkd. 2017;234(4):567\u2013570. https:\/\/doi.org\/10.1055\/s-0042-121315.","DOI":"10.1055\/s-0042-121315"},{"issue":"12","key":"393_CR70","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2169\/internalmedicine.0215-17","volume":"57","author":"Y Fujita","year":"2018","unstructured":"Fujita Y, Fukui S, Endo Y, et al. Peripheral ulcerative keratitis associated with granulomatosis with polyangiitis emerging despite cyclophosphamide, successfully treated with rituximab. Intern Med. 2018;57(12):1783\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.0215-17.","journal-title":"Intern Med"},{"issue":"5","key":"393_CR71","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.autrev.2019.03.001","volume":"18","author":"MA P\u00e9rez-Jacoiste As\u00edn","year":"2019","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Charles P, Rothschild PR, et al. Ocular involvement in granulomatosis with polyangiitis: a single-center cohort study on 63 patients. Autoimmun Rev. 2019;18(5):493\u2013500. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.001.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"393_CR72","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4103\/ijo.IJO_2249_19","volume":"68","author":"SI Murthy","year":"2020","unstructured":"Murthy SI, Shah S, Bagga B, Dudam R. Rituximab therapy combined with methotrexate for severe necrotizing scleritis in a case of granulomatosis with polyangiitis. Indian J Ophthalmol. 2020;68(9):1981\u20133. https:\/\/doi.org\/10.4103\/ijo.IJO_2249_19.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"393_CR73","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jbspin.2013.07.011","volume":"81","author":"F Caso","year":"2014","unstructured":"Caso F, Fiocco U, Costa L, Sfriso P, Punzi L, Doria A. Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine. 2014;81(2):190\u20132. https:\/\/doi.org\/10.1016\/j.jbspin.2013.07.011.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"393_CR74","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/j.jcjo.2015.05.009","volume":"50","author":"AK Soon","year":"2015","unstructured":"Soon AK, Chan TY. An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia. Can J Ophthalmol. 2015;50(4):e60\u20133. https:\/\/doi.org\/10.1016\/j.jcjo.2015.05.009.","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"393_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11102-014-0592-7","volume":"18","author":"C Xu","year":"2015","unstructured":"Xu C, Ricciuti A, Caturegli P, Keene CD, Kargi AY. Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab. Pituitary. 2015;18(4):441\u20137. https:\/\/doi.org\/10.1007\/s11102-014-0592-7.","journal-title":"Pituitary"},{"issue":"5","key":"393_CR76","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5935\/0004-2749.20160097","volume":"79","author":"TS Fidelix","year":"2016","unstructured":"Fidelix TS, Vieira LA, Trevisani VF. Management of necrotizing scleritis after pterygium surgery with rituximab. Arq Bras Oftalmol. 2016;79(5):339\u201341. https:\/\/doi.org\/10.5935\/0004-2749.20160097.","journal-title":"Arq Bras Oftalmol"},{"issue":"10","key":"393_CR77","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s10067-016-3527-z","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Sota J, Tosi GM, et al. The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol. 2017;36(10):2307\u201318. https:\/\/doi.org\/10.1007\/s10067-016-3527-z.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"393_CR78","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/rheumatology\/kem052","volume":"46","author":"C Botsios","year":"2007","unstructured":"Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatol (Oxford). 2007;46(6):1042\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/kem052.","journal-title":"Rheumatol (Oxford)"},{"key":"393_CR79","doi-asserted-by":"publisher","first-page":"8294560","DOI":"10.1155\/2020\/8294560","volume":"2020","author":"C Fabiani","year":"2020","unstructured":"Fabiani C, Sota J, Sainz-de-la-Maza M, et al. New potential weapons for refractory scleritis in the era of targeted therapy. Mediators Inflamm. 2020;2020:8294560. https:\/\/doi.org\/10.1155\/2020\/8294560.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"393_CR80","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","volume":"36","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Sota J, et al. IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol. 2017;36(7):1459\u201369. https:\/\/doi.org\/10.1007\/s10067-017-3672-z.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"393_CR81","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1111\/aos.12720","volume":"93","author":"J Tode","year":"2015","unstructured":"Tode J, Zeuner R, Saeger M, Roider J, N\u00f6lle B. Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis. Acta Ophthalmol. 2015;93(8):e683\u20134. https:\/\/doi.org\/10.1111\/aos.12720.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"393_CR82","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1111\/aos.13015","volume":"94","author":"S Silpa-Archa","year":"2016","unstructured":"Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400\u20136. https:\/\/doi.org\/10.1111\/aos.13015.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"393_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/09273948.2019.1617885","volume":"28","author":"HJ Poelman","year":"2020","unstructured":"Poelman HJ, Van Daele PLA, Rothova A. Successful tocilizumab treatment for scleritis. Ocul Immunol Inflamm. 2020;28(2):285\u20137. https:\/\/doi.org\/10.1080\/09273948.2019.1617885.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"393_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/09273948.2020.1763405","volume":"29","author":"R Farhat","year":"2021","unstructured":"Farhat R, Clavel G, Villeneuve D, et al. Sustained remission with tocilizumab in refractory relapsing polychondritis with ocular involvement: a case series. Ocul Immunol Inflamm. 2021;29(1):9\u201313. https:\/\/doi.org\/10.1080\/09273948.2020.1763405.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"393_CR85","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/03009742.2016.1275774","volume":"46","author":"H Shimizu","year":"2017","unstructured":"Shimizu H, Nishioka H. Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis. Scand J Rheumatol. 2017;46(5):418\u20139. https:\/\/doi.org\/10.1080\/03009742.2016.1275774.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"393_CR86","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3899\/jrheum.170234","volume":"44","author":"E Michael","year":"2017","unstructured":"Michael E, Lange EL, Guest S. Paradoxical nodular scleritis during tocilizumab therapy: a case report. J Rheumatol. 2017;44(11):1760\u20131. https:\/\/doi.org\/10.3899\/jrheum.170234.","journal-title":"J Rheumatol"},{"key":"393_CR87","doi-asserted-by":"publisher","unstructured":"Dominguez-Casas LC, S\u00e1nchez-Bilbao L, Calvo-R\u00edo V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. 2020;50(4):608\u2013615. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.023.","DOI":"10.1016\/j.semarthrit.2020.03.023"},{"issue":"11","key":"393_CR88","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3899\/jrheum.151389","volume":"43","author":"C Birolo","year":"2016","unstructured":"Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol. 2016;43(11):2068\u201373. https:\/\/doi.org\/10.3899\/jrheum.151389.","journal-title":"J Rheumatol"},{"key":"393_CR89","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/OARRR.S263259","volume":"12","author":"S Matsumoto","year":"2020","unstructured":"Matsumoto S, Matsumoto K, Takaya H, Otake H, Mashima H. Efficacy of ustekinumab against spondyloarthritis associated with Crohn\u2019s disease: a case report and review of the literature. Open Access Rheumatol. 2020;12:133\u20137. https:\/\/doi.org\/10.2147\/OARRR.S263259.","journal-title":"Open Access Rheumatol"},{"issue":"4","key":"393_CR90","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","volume":"110","author":"GN Papaliodis","year":"2003","unstructured":"Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110(4):786\u20139. https:\/\/doi.org\/10.1016\/S0161-6420(02)01932-2.","journal-title":"Ophthalmology"},{"issue":"8","key":"393_CR91","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/ICO.0000000000000180","volume":"33","author":"KR Kommaraju","year":"2014","unstructured":"Kommaraju KR, Moroi S, Demirci H. Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. Cornea. 2014;33(8):873\u20134. https:\/\/doi.org\/10.1097\/ICO.0000000000000180.","journal-title":"Cornea"},{"issue":"2","key":"393_CR92","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u201328.","journal-title":"Clin Exp Rheumatol"},{"key":"393_CR93","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","volume":"13","author":"MA Paley","year":"2018","unstructured":"Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53\u20135. https:\/\/doi.org\/10.1016\/j.ajoc.2018.12.001.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"393_CR94","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.4103\/ijo.IJO_534_20","volume":"68","author":"R Pyare","year":"2020","unstructured":"Pyare R, Kaushik V, Dutta Majumder P, Biswas J. Tofacitinib in recalcitrant scleritis: first case report from India. Indian J Ophthalmol. 2020;68(9):1988\u201390. https:\/\/doi.org\/10.4103\/ijo.IJO_534_20.","journal-title":"Indian J Ophthalmol"},{"key":"393_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108078","volume":"197","author":"DPC Vergouwen","year":"2020","unstructured":"Vergouwen DPC, Rothova A, Berge JCT, et al. Current insights in the pathogenesis of scleritis. Exp Eye Res. 2020;197: 108078. https:\/\/doi.org\/10.1016\/j.exer.2020.108078.","journal-title":"Exp Eye Res"},{"issue":"7","key":"393_CR96","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S0161-6420(99)00719-8","volume":"106","author":"WP Riono","year":"1999","unstructured":"Riono WP, Hidayat AA, Rao NA. Scleritis: a clinicopathologic study of 55 cases. Ophthalmology. 1999;106(7):1328\u201333. https:\/\/doi.org\/10.1016\/S0161-6420(99)00719-8.","journal-title":"Ophthalmology"},{"issue":"1","key":"393_CR97","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12886-020-01769-3","volume":"21","author":"MK Berkenstock","year":"2021","unstructured":"Berkenstock MK, Carey AR. Health system wide \u201cbig data\u201d analysis of rheumatologic conditions and scleritis. BMC Ophthalmol. 2021;21(1):14. https:\/\/doi.org\/10.1186\/s12886-020-01769-3.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"393_CR98","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10384-019-00674-7","volume":"63","author":"A Yoshida","year":"2019","unstructured":"Yoshida A, Watanabe M, Okubo A, Kawashima H. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis). Jpn J Ophthalmol. 2019;63(5):417\u201324. https:\/\/doi.org\/10.1007\/s10384-019-00674-7.","journal-title":"Jpn J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-021-00393-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T07:53:44Z","timestamp":1636703624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-021-00393-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1007\/s40123-021-00393-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"15 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}